Ayahuasca: pharmacology, safety, and therapeutic effects.

IF 3.4 3区 医学 Q2 CLINICAL NEUROLOGY
Rafael Guimarães Dos Santos, Jaime Eduardo Cecilio Hallak
{"title":"Ayahuasca: pharmacology, safety, and therapeutic effects.","authors":"Rafael Guimarães Dos Santos, Jaime Eduardo Cecilio Hallak","doi":"10.1017/S109285292400213X","DOIUrl":null,"url":null,"abstract":"<p><p>Ayahuasca is a botanical hallucinogen traditionally used for therapeutic and ritual purposes by indigenous groups from Northwestern Amazonian countries such as Brazil, Peru, Colombia, and Ecuador. Ayahuasca is made by the decoction of two plants, which are rich in the 5-HT1A/2A partial agonist dimethyltryptamine or DMT (from the leaves of the <i>Psychotria viridis</i> bush) and β-carbolines such as harmine, from the stalks of the <i>Banisteriopsis caapi</i> vine. There is an increasing interest in the possible therapeutic effects of ayahuasca, especially for psychiatric disorders (major depression, posttraumatic stress disorder, and substance use disorder). This review summarizes information on the pharmacology, safety, and therapeutic potentials of ayahuasca. Although human experimental and naturalist studies published until now suggest a good safety and tolerability profile, often associated with improvements in depressive and anxious symptoms, there are few controlled studies, with small sample sizes, using only single doses, and with short follow-ups. Potential benefits of ayahuasca should be evaluated in larger samples in both experimental and observational studies and using different doses in controlled trials.</p>","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"e2"},"PeriodicalIF":3.4000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Spectrums","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S109285292400213X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Ayahuasca is a botanical hallucinogen traditionally used for therapeutic and ritual purposes by indigenous groups from Northwestern Amazonian countries such as Brazil, Peru, Colombia, and Ecuador. Ayahuasca is made by the decoction of two plants, which are rich in the 5-HT1A/2A partial agonist dimethyltryptamine or DMT (from the leaves of the Psychotria viridis bush) and β-carbolines such as harmine, from the stalks of the Banisteriopsis caapi vine. There is an increasing interest in the possible therapeutic effects of ayahuasca, especially for psychiatric disorders (major depression, posttraumatic stress disorder, and substance use disorder). This review summarizes information on the pharmacology, safety, and therapeutic potentials of ayahuasca. Although human experimental and naturalist studies published until now suggest a good safety and tolerability profile, often associated with improvements in depressive and anxious symptoms, there are few controlled studies, with small sample sizes, using only single doses, and with short follow-ups. Potential benefits of ayahuasca should be evaluated in larger samples in both experimental and observational studies and using different doses in controlled trials.

死藤水:药理学、安全性和治疗效果。
死藤水是一种植物致幻剂,巴西、秘鲁、哥伦比亚和厄瓜多尔等亚马逊河西北部国家的土著群体传统上将其用于治疗和仪式目的。死藤水是由两种植物煎煮而成的,这两种植物富含 5-HT1A/2A 部分激动剂二甲基色胺或 DMT(取自 Psychotria viridis 灌木的叶子)和β-胭脂虫碱(如哈明,取自 Banisteriopsis caapi 藤蔓的茎秆)。人们越来越关注死藤水可能产生的治疗效果,尤其是对精神疾病(重度抑郁症、创伤后应激障碍和药物使用障碍)的治疗效果。本综述总结了有关死藤水的药理学、安全性和治疗潜力的信息。尽管迄今为止发表的人体实验和自然科学研究表明,死藤水具有良好的安全性和耐受性,通常与抑郁和焦虑症状的改善有关,但对照研究很少,样本量小,仅使用单剂量,随访时间短。死藤水的潜在益处应在更大样本的实验和观察研究中进行评估,并在对照试验中使用不同剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CNS Spectrums
CNS Spectrums 医学-精神病学
CiteScore
6.20
自引率
6.10%
发文量
239
审稿时长
>12 weeks
期刊介绍: CNS Spectrums covers all aspects of the clinical neurosciences, neurotherapeutics, and neuropsychopharmacology, particularly those pertinent to the clinician and clinical investigator. The journal features focused, in-depth reviews, perspectives, and original research articles. New therapeutics of all types in psychiatry, mental health, and neurology are emphasized, especially first in man studies, proof of concept studies, and translational basic neuroscience studies. Subject coverage spans the full spectrum of neuropsychiatry, focusing on those crossing traditional boundaries between neurology and psychiatry.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信